Sierra Oncology, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Vancouver Canada (2003)
Status: Acquired by GlaxoSmithKline (2022)

Organization Overview

First Clinical Trial
2010
NCT01191775
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Sierra Oncology, Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

danazol (danocrine) (1 trial)

momelotinib (Ojjaara) (1 trial)

Drugs in Phase 2 Trials (1)

pnt2258 (4 trials)

Drugs in Phase 1 Trials (3)

cisplatin (platinol) (1 trial)

gemcitabine (gemzar) (1 trial)

sra737 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Melanoma (Phase 1)

Polycythemia (Phase 3)

Polycythemia Vera (Phase 3)

Primary Myelofibrosis (Phase 3)

Prostatic Neoplasms (Phase 1)

Thrombocythemia, Essential (Phase 3)

Thrombocytosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 6